<?xml version="1.0" encoding="UTF-8" standalone="no" ?>
<!DOCTYPE ichicsr SYSTEM "http://www.fda.gov/cder/aerssub/icsr-xml-v2.1.dtd">
<ichicsr lang="en">
  <ichicsrmessageheader lang="en">
    <messagetype>ichicsr</messagetype>
    <messageformatversion>2.1</messageformatversion>
    <messageformatrelease>2.0</messageformatrelease>
    <messagenumb>CEL000000000001289237</messagenumb>
    <messagesenderidentifier>CELGENE</messagesenderidentifier>
    <messagereceiveridentifier>ZZFDA</messagereceiveridentifier>
    <messagedateformat>204</messagedateformat>
    <messagedate>20130125102355</messagedate>
  </ichicsrmessageheader>
  <safetyreport lang="en">
    <safetyreportversion lang="en">0</safetyreportversion>
    <safetyreportid lang="en">US-CELGENEUS-163-21880-13013361</safetyreportid>
    <primarysourcecountry>US</primarysourcecountry>
    <occurcountry>US</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20130125</transmissiondate>
    <reporttype>1</reporttype>
    <serious>1</serious>
    <seriousnessdeath>1</seriousnessdeath>
    <seriousnessother>2</seriousnessother>
    <receivedateformat>102</receivedateformat>
    <receivedate>20130121</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20130121</receiptdate>
    <additionaldocument>2</additionaldocument>
    <fulfillexpeditecriteria>1</fulfillexpeditecriteria>
    <companynumb lang="en">US-CELGENEUS-163-21880-13013361</companynumb>
    <medicallyconfirm>1</medicallyconfirm>
    <linkedreport>
      <linkreportnumb>US-CELGENE-163-21880-12120279</linkreportnumb>
    </linkedreport>
    <primarysource>
      <reportertitle>Dr.</reportertitle>
      <reportergivename>Myo</reportergivename>
      <reporterfamilyname>Min</reporterfamilyname>
      <reporterstreet>602 South Atwood Rd.</reporterstreet>
      <reportercity>Bel Air</reportercity>
      <reporterstate>MD</reporterstate>
      <reporterpostcode>21014</reporterpostcode>
      <reportercountry>US</reportercountry>
      <qualification>1</qualification>
    </primarysource>
    <sender>
      <sendertype>1</sendertype>
      <senderorganization>CELGENEUS</senderorganization>
      <senderdepartment>Global Drug Safety</senderdepartment>
      <sendertitle>Manager</sendertitle>
      <sendergivename>Vivian</sendergivename>
      <senderfamilyname>Fonseca</senderfamilyname>
      <senderstreetaddress>300 Connell Drive, Suite 6000</senderstreetaddress>
      <sendercity>Berkeley Heights</sendercity>
      <senderstate>NJ</senderstate>
      <senderpostcode>07922</senderpostcode>
      <sendercountrycode>US</sendercountrycode>
      <sendertel>9082190331</sendertel>
      <senderfax>9086739115</senderfax>
      <senderemailaddress>vfonseca@celgene.com</senderemailaddress>
    </sender>
    <receiver>
      <receivertype>2</receivertype>
      <receiverorganization>FDAPM</receiverorganization>
      <receivergivename>Roger</receivergivename>
      <receivermiddlename>A</receivermiddlename>
      <receiverfamilyname>Goetsch</receiverfamilyname>
      <receivercountrycode>US</receivercountrycode>
    </receiver>
    <patient lang="en">
      <patientinitial>C-D</patientinitial>
      <patientbirthdateformat>102</patientbirthdateformat>
      <patientbirthdate>19320401</patientbirthdate>
      <patientsex>2</patientsex>
      <medicalhistoryepisode>
        <patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
        <patientepisodename>10013661</patientepisodename>
      </medicalhistoryepisode>
      <medicalhistoryepisode>
        <patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
        <patientepisodename>10040539</patientepisodename>
      </medicalhistoryepisode>
      <patientdeath>
        <patientdeathdateformat>602</patientdeathdateformat>
        <patientdeathdate>2013</patientdeathdate>
        <patientdeathcause>
          <patientdeathreportmeddraversion>15.1</patientdeathreportmeddraversion>
          <patientdeathreport>10063378</patientdeathreport>
        </patientdeathcause>
      </patientdeath>
      <reaction>
        <primarysourcereaction lang="en">PASSED AWAY</primarysourcereaction>
        <reactionmeddraversionllt>15.1</reactionmeddraversionllt>
        <reactionmeddrallt>10011906</reactionmeddrallt>
        <reactionmeddraversionpt>15.1</reactionmeddraversionpt>
        <reactionmeddrapt>10011906</reactionmeddrapt>
        <termhighlighted>3</termhighlighted>
        <reactionstartdateformat>610</reactionstartdateformat>
        <reactionstartdate>201301</reactionstartdate>
        <reactionfirsttime>4</reactionfirsttime>
        <reactionfirsttimeunit>802</reactionfirsttimeunit>
        <reactionoutcome>5</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>REVLIMID</medicinalproduct>
        <obtaindrugcountry>US</obtaindrugcountry>
        <drugauthorizationnumb>21-880</drugauthorizationnumb>
        <drugauthorizationcountry>US</drugauthorizationcountry>
        <drugauthorizationholder>Celgene Corporation</drugauthorizationholder>
        <drugstructuredosagenumb>10</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>21</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>28</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext lang="en">10 Milligram</drugdosagetext>
        <drugdosageform lang="en">Capsules</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindicationmeddraversion>15.1</drugindicationmeddraversion>
        <drugindication>10028228</drugindication>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20120906</drugstartdate>
        <drugstartperiod>4</drugstartperiod>
        <drugstartperiodunit>802</drugstartperiodunit>
        <actiondrug>6</actiondrug>
        <drugrecurreadministration>3</drugrecurreadministration>
        <activesubstance>
          <activesubstancename>LENALIDOMIDE</activesubstancename>
        </activesubstance>
        <drugreactionrelatedness lang="en">
          <drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
          <drugreactionasses>10011906</drugreactionasses>
          <drugassessmentsource lang="en">Reporter</drugassessmentsource>
          <drugresult lang="en">Unknown</drugresult>
        </drugreactionrelatedness>
      </drug>
      <summary lang="en">
        <narrativeincludeclinical lang="en">PASSED AWAY

(USA) Initial information was received on 21Jan2013 via a contract pharmacy from the prescriber' office regarding an 80 year old female who received Revlimid 10 mg PO daily for 21 days every 4 weeks from 06Sep2012 for the treatment of multiple myeloma.  Lot number was A0160A and expiration date was 31Dec2014.  Relevant medical history included allergy to tetanus toxoid and scallops.  Concomitant medications were not reported.

The patient was reported to have passed away last week (Jan2013).  The date of death and cause of death were not specified.  The reporter causally assessed the patient's death to Revlimid as unknown.  Additional information will be requested from the prescriber.

Cross-reference this case to 163-21880-12120279 (anemia).</narrativeincludeclinical>
        <sendercomment lang="en">The temporal relationship between therapy and PASSED AWAY suggests that a causal relationship is possible, but underlying disease could provide an alternative explanation.  Incomplete information does not permit a meaningful causality assessment.  Additional information will be requested from the prescriber to assist in providing a relevant causality assessment of the event.</sendercomment>
      </summary>
    </patient>
  </safetyreport>
</ichicsr>
